Literature DB >> 20375595

TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.

D M Appledorn1, S Patial, S Godbehere, N Parameswaran, A Amalfitano.   

Abstract

The use of Adenovirus (Ad)-based vectors has proven to be a useful platform for the development of gene therapy and vaccine protocols. The immunological mechanisms underlying these properties need to be identified and understood to foster safer, more efficacious use of this important gene transfer platform. Our recent studies have confirmed an important role for MyD88 dependent toll-like receptor (TLR) pathways as mediators of these responses. In this study, we confirm that TLR3, TLR4 and TRIF (TIR-domain-containing adapter-inducing interferon-beta) can also have augmentative or inhibitory roles during Ad-induced immune responses. Importantly, our studies revealed that TLR4 acts to suppress several aspects of the Ad-induced innate immune response, a finding not previously reported for this TLR in any model system. In addition, using MyD88 and TRIF double knockout mice, we demonstrate that the MyD88 and TRIF adaptor proteins can play either additive or redundant roles in mediating certain aspects of Ad vector-induced innate and adaptive immune responses. Furthering this complexity, our model system strongly suggests that non-TLR based systems must not only exist, but also have a significant role to play during Ad vector-mediated induction of adaptive immune responses. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20375595      PMCID: PMC2853581          DOI: 10.1159/000207194

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  35 in total

1.  Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies.

Authors:  H Jiang; Z Wang; D Serra; M M Frank; A Amalfitano
Journal:  Mol Ther       Date:  2004-12       Impact factor: 11.454

2.  Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

Review 3.  Triggering TLR signaling in vaccination.

Authors:  David van Duin; Ruslan Medzhitov; Albert C Shaw
Journal:  Trends Immunol       Date:  2005-11-23       Impact factor: 16.687

4.  Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.

Authors:  Amanda L Gavin; Kasper Hoebe; Bao Duong; Takayuki Ota; Christopher Martin; Bruce Beutler; David Nemazee
Journal:  Science       Date:  2006-12-22       Impact factor: 47.728

5.  Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.

Authors:  Anne Kiang; Zachary C Hartman; Ruth S Everett; Delila Serra; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Mol Ther       Date:  2006-06-02       Impact factor: 11.454

6.  Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted.

Authors:  A Amalfitano; M A Hauser; H Hu; D Serra; C R Begy; J S Chamberlain
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages.

Authors:  Narayanan Parameswaran; Christina S Pao; Kristi S Leonhard; Dong Soo Kang; Michelle Kratz; Steven C Ley; Jeffrey L Benovic
Journal:  J Biol Chem       Date:  2006-09-15       Impact factor: 5.157

8.  Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.

Authors:  Senad Divanovic; Aurelien Trompette; Sowsan F Atabani; Rajat Madan; Douglas T Golenbock; Alberto Visintin; Robert W Finberg; Alexander Tarakhovsky; Stefanie N Vogel; Yasmine Belkaid; Evelyn A Kurt-Jones; Christopher L Karp
Journal:  Nat Immunol       Date:  2005-04-24       Impact factor: 25.606

9.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.

Authors:  Steven E Raper; Narendra Chirmule; Frank S Lee; Nelson A Wivel; Adam Bagg; Guang-ping Gao; James M Wilson; Mark L Batshaw
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

10.  Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance.

Authors:  N Wolins; J Lozier; T L Eggerman; E Jones; E Aguilar-Córdova; J G Vostal
Journal:  Br J Haematol       Date:  2003-12       Impact factor: 6.998

View more
  20 in total

1.  Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; Sarah Godbehere; Sergey S Seregin; Andrea Amalfitano
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

2.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors:  Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

3.  A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; William Depas; Sergey S Seregin; Chyong-Jy J Liu; Nathan Schuldt; Darin Quach; Dionisia Quiroga; Sarah Godbehere; Igor Zlatkin; Sungjin Kim; J Justin McCormick; Andrea Amalfitano
Journal:  PLoS One       Date:  2010-03-08       Impact factor: 3.240

4.  beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2.

Authors:  Sergey S Seregin; Daniel M Appledorn; Sonika Patial; M Bujold; W Nance; S Godbehere; Narayanan Parameswaran; Andrea Amalfitano
Journal:  Virus Res       Date:  2009-11-06       Impact factor: 3.303

5.  In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens.

Authors:  Fadel S Alyaqoub; Yasser A Aldhamen; Benjamin J Koestler; Eric L Bruger; Sergey S Seregin; Cristiane Pereira-Hicks; Sarah Godbehere; Christopher M Waters; Andrea Amalfitano
Journal:  J Immunol       Date:  2016-01-20       Impact factor: 5.422

6.  Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.

Authors:  Stefania Capone; Mariarosaria Naddeo; Anna Morena D'Alise; Adele Abbate; Fabiana Grazioli; Annunziata Del Gaudio; Mariarosaria Del Sorbo; Maria Luisa Esposito; Virginia Ammendola; Gemma Perretta; Alessandra Taglioni; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori
Journal:  Mol Ther       Date:  2014-01-30       Impact factor: 11.454

7.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

8.  Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives.

Authors:  Francesco Vetrini; Philip Ng
Journal:  Viruses       Date:  2010-09-03       Impact factor: 5.818

9.  TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Charles F Aylsworth; Sarah Godbehere; Chyong-Jy Joyce Liu; Dionisia Quiroga; Andrea Amalfitano
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

10.  Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1.

Authors:  Érica Araújo Mendes; Flavio G Fonseca; Bárbara M Casério; Janaína P Colina; Ricardo Tostes Gazzinelli; Braulia C Caetano
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.